- 作者：Hiroshi Onishi M.D.&lowast ; ; ; honishi@yamanashi.ac.jp ; Hiroki Shirato M.D.&dagger ; ; Yasushi Nagata M.D.&Dagger ; ; Masahiro Hiraoka M.D.§ ; ; Masaharu Fujino M.D.&dagger ; ; ; &lowast ; ; Kotaro Gomi M.D.?/sup> ; Katsuyuki Karasawa M.D.¶ ; ; Kazushige Hayakawa M.D.# ; Yuzuru Niibe M.D.# ; Yoshihiro Takai M.D.&lowast ; &lowast ; ; Tomoki Kimura M.D.&dagger ; &dagger ; ; Atsuya Takeda M.D.&Dagger ; &Dagger ; ; Atsushi Ouchi M.D.§ ; § ; ; Masato Hareyama M.D.¡¬?/sup> ; Masaki Kokubo M.D.¶ ; ¶ ; ; Takuyo Kozuka M.D.## ; Takuro Arimoto M.D.&lowast ; &lowast ; &lowast ; ; Ryusuke Hara M.D.&dagger ; &dagger ; &dagger ; ; Jun Itami M.D.&Dagger ; &Dagger ; &Dagger ; ; Tsutomu Araki M.D.&lowast ;
- 刊名：International Journal of Radiation Oncology*Biology*Physics
- 出版年：2011
- 出版时间：1 December 2011
- 年：2011
- 卷：81
- 期：5
- 页码：1352-1358
- 全文大小：347 K
Purpose
To review treatment outcomes for stereotactic body radiotherapy (SBRT) in medically operable patients with Stage I non¨Csmall-cell lung cancer (NSCLC), using a Japanese multi-institutional database.Patients and Methods
Between 1995 and 2004, a total of 87 patients with Stage I NSCLC (median age, 74 years; T1N0M0, n = 65; T2N0M0, n = 22) who were medically operable but refused surgery were treated using SBRT alone in 14 institutions. Stereotactic three-dimensional treatment was performed using noncoplanar dynamic arcs or multiple static ports. Total dose was 45?2.5 Gy at the isocenter, administered in 3?0 fractions. Median calculated biological effective dose was 116 Gy (range, 100?41 Gy). Data were collected and analyzed retrospectively.
Results
During follow-up (median, 55 months), cumulative local control rates for T1 and T2 tumors at 5 years after SBRT were 92 % and 73 % , respectively. Pulmonary complications above Grade 2 arose in 1 patient (1.1 % ). Five-year overall survival rates for Stage IA and IB subgroups were 72 % and 62 % , respectively. One patient who developed local recurrences safely underwent salvage surgery.
Conclusion
Stereotactic body radiotherapy is safe and promising as a radical treatment for operable Stage I NSCLC. The survival rate for SBRT is potentially comparable to that for surgery.